DoD Taking Applications For $75K Horizon Grant

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The Department of Defense is taking applications for its Horizon Award, which offers up to $75,000 in funding to support junior-level scientists to conduct impactful research with the mentorship of an experienced cancer researcher.

The award is for principal investigators, both pre-doctoral candidates and postdoctoral fellows are eligible, and mentors that have a strong record of funding and publications. The PI and mentor must be from the same organization.

They must address at least one of the congressionally directed FY15 PRCRP Topic Areas and are encouraged to address at least one of the FY15 PRCRP Military Relevance Focus Areas. Research applications in the areas of breast, prostate, lung (excluding mesothelioma), or ovarian cancer will not be accepted.

The FY15 PRCRP Topic Areas are: cancers of the kidney, liver, pancreas, stomach or colorectal tract; melanoma and other skin cancers; myeloproliferative disorders; listeria vaccines for cancer; mesothelioma; and neuroblastoma. Liver and stomach cancer have been newly added for 2015.

The FY15 Military Relevance Focus Areas are: Militarily relevant risk factors associated with cancer (e.g., ionizing radiation, chemicals, infectious agents, and environmental carcinogens); and gaps in cancer prevention, screening, early detection, diagnosis, treatment, and/or survivorship that may affect the general population but have a particularly profound impact on the health and well-being of military members, veterans, and their beneficiaries.

Full applications are due Aug. 11. Clinical trials are not allowed and preliminary data are not required. The maximum period of performance is one year.

A pre-application is required through the electronic Biomedical Research Application Portal at http://eBRAP.org prior to the pre-application deadline.

Program announcements and general application instructions are available at www.grants.gov.

YOU MAY BE INTERESTED IN

At the Sept. 4 meeting of the National Cancer Advisory Board, NCI Principal Deputy Director Douglas R. Lowy provided an overview of how NCI is weathering the maelstrom of executive orders, policy changes, and funding uncertainties that has come down on federal agencies and research institutes since Donald Trump’s inauguration in January. 
A Senate hearing that the administration hoped would be a routine check-in on the president’s 2026 MAHA-driven healthcare agenda erupted into a political firestorm as senators jumped at their first opportunity to confront HHS Secretary Robert F. Kennedy Jr. over the chaos engulfing the Centers for Disease Control and Prevention.
In December 1971, President Richard Nixon signed the National Cancer Act and declared a “War on Cancer.” In the past 54 years, the U.S. has invested $180 billion nominally, or approximately $322 billion when adjusted for inflation, in cancer research. This investment has paid dividends with more than 100 anticancer drugs brought to market in half a century—virtually all traceable to National Cancer Institute funding. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login